HK1167101A1 - Compositions and methods for treatment of multiple sclerosis - Google Patents
Compositions and methods for treatment of multiple sclerosisInfo
- Publication number
- HK1167101A1 HK1167101A1 HK12107888.6A HK12107888A HK1167101A1 HK 1167101 A1 HK1167101 A1 HK 1167101A1 HK 12107888 A HK12107888 A HK 12107888A HK 1167101 A1 HK1167101 A1 HK 1167101A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- treatment
- methods
- multiple sclerosis
- sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photographic Developing Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
| PCT/NZ2010/000112 WO2010147484A1 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1167101A1 true HK1167101A1 (en) | 2013-02-01 |
Family
ID=42646236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK12107888.6A HK1167101A1 (en) | 2009-06-16 | 2012-08-10 | Compositions and methods for treatment of multiple sclerosis |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8389479B2 (hr) |
| EP (1) | EP2442832B1 (hr) |
| JP (1) | JP5646617B2 (hr) |
| CN (1) | CN102458476B (hr) |
| AU (1) | AU2010260585B2 (hr) |
| BR (1) | BRPI1009606A2 (hr) |
| CA (1) | CA2688766C (hr) |
| CY (1) | CY1115714T1 (hr) |
| DK (1) | DK2442832T3 (hr) |
| ES (1) | ES2521565T3 (hr) |
| HK (1) | HK1167101A1 (hr) |
| HR (1) | HRP20141035T1 (hr) |
| IL (1) | IL216993A (hr) |
| IN (1) | IN2012DN00167A (hr) |
| MX (1) | MX2011013661A (hr) |
| NZ (1) | NZ577731A (hr) |
| PL (1) | PL2442832T3 (hr) |
| PT (1) | PT2442832E (hr) |
| SI (1) | SI2442832T1 (hr) |
| SM (1) | SMT201400165B (hr) |
| WO (1) | WO2010147484A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709448B2 (en) * | 2008-04-01 | 2014-04-29 | Innate Immunotherapeutics Ltd. | Anti-infective agents and uses thereof |
| PL3326645T3 (pl) | 2010-10-25 | 2020-09-21 | Biogen Ma Inc. | Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2017059486A1 (en) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of epilepsy |
| CA2926507A1 (en) * | 2015-10-06 | 2017-04-06 | Innate Immunotherapeutics Limited | Compositions and methods for protection and/or repair of the nervous system |
| WO2017070731A1 (en) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of alzheimer's disease |
| WO2018178973A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| EP3793583A4 (en) * | 2018-05-18 | 2022-03-09 | Université Laval | USE OF A NOD2 AGONIST FOR THE TREATMENT, PROPHYLAXIS AND/OR DELAYING THE ONSET OF MULTIPLE SCLEROSIS AND ALZHEIMER'S DISEASE |
| WO2020010221A1 (en) * | 2018-07-03 | 2020-01-09 | University Of Florida Research Foundation, Inc. | Microparticle systems and their use for the treatment of multiple sclerosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001502315A (ja) * | 1996-10-10 | 2001-02-20 | プローブ・インターナショナル | ウイルス感染を処置するための組成物および方法 |
| EA200700263A1 (ru) * | 2004-07-01 | 2007-06-29 | Кебенхавнс Университет | Способ лечения и профилактики рассеянного склероза путём лечения лептоспирозной инфекции |
| US8603978B2 (en) * | 2006-12-01 | 2013-12-10 | The United States of America, as represented by the Secretary, Department of Health and Humand Services | Use of muramyl dipeptide (MDP) for treating inflammation |
| JP2008251608A (ja) | 2007-03-29 | 2008-10-16 | Casio Comput Co Ltd | 半導体装置およびその製造方法 |
| WO2008150182A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treatment of anthrax |
| WO2008150181A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treating anthrax exposure associated conditions |
-
2009
- 2009-06-16 NZ NZ577731A patent/NZ577731A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,733 patent/US8389479B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2688766A patent/CA2688766C/en not_active Expired - Fee Related
-
2010
- 2010-01-16 CN CN201080026791.5A patent/CN102458476B/zh not_active Expired - Fee Related
- 2010-01-16 BR BRPI1009606A patent/BRPI1009606A2/pt not_active Application Discontinuation
- 2010-06-16 SI SI201030779T patent/SI2442832T1/sl unknown
- 2010-06-16 ES ES10789788.6T patent/ES2521565T3/es active Active
- 2010-06-16 WO PCT/NZ2010/000112 patent/WO2010147484A1/en active Application Filing
- 2010-06-16 DK DK10789788.6T patent/DK2442832T3/da active
- 2010-06-16 AU AU2010260585A patent/AU2010260585B2/en not_active Ceased
- 2010-06-16 MX MX2011013661A patent/MX2011013661A/es active IP Right Grant
- 2010-06-16 JP JP2012516022A patent/JP5646617B2/ja not_active Expired - Fee Related
- 2010-06-16 PT PT107897886T patent/PT2442832E/pt unknown
- 2010-06-16 EP EP10789788.6A patent/EP2442832B1/en active Active
- 2010-06-16 PL PL10789788T patent/PL2442832T3/pl unknown
- 2010-06-16 IN IN167DEN2012 patent/IN2012DN00167A/en unknown
-
2011
- 2011-12-15 IL IL216993A patent/IL216993A/en not_active IP Right Cessation
-
2012
- 2012-08-10 HK HK12107888.6A patent/HK1167101A1/xx not_active IP Right Cessation
-
2014
- 2014-10-27 HR HRP20141035AT patent/HRP20141035T1/hr unknown
- 2014-11-03 CY CY20141100908T patent/CY1115714T1/el unknown
- 2014-11-04 SM SM201400165T patent/SMT201400165B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN00167A (hr) | 2015-04-17 |
| IL216993A0 (en) | 2012-02-29 |
| JP2012530132A (ja) | 2012-11-29 |
| EP2442832A1 (en) | 2012-04-25 |
| US20100317589A1 (en) | 2010-12-16 |
| ES2521565T3 (es) | 2014-11-12 |
| US8389479B2 (en) | 2013-03-05 |
| BRPI1009606A2 (pt) | 2016-10-11 |
| SI2442832T1 (sl) | 2014-12-31 |
| IL216993A (en) | 2016-03-31 |
| DK2442832T3 (da) | 2014-11-10 |
| WO2010147484A8 (en) | 2012-07-19 |
| EP2442832B1 (en) | 2014-08-06 |
| PL2442832T3 (pl) | 2015-01-30 |
| CN102458476A (zh) | 2012-05-16 |
| WO2010147484A1 (en) | 2010-12-23 |
| SMT201400165B (it) | 2015-01-15 |
| CA2688766C (en) | 2015-06-30 |
| NZ577731A (en) | 2010-08-27 |
| EP2442832A4 (en) | 2013-07-03 |
| CY1115714T1 (el) | 2017-01-25 |
| AU2010260585A8 (en) | 2012-06-14 |
| MX2011013661A (es) | 2012-05-22 |
| JP5646617B2 (ja) | 2014-12-24 |
| CA2688766A1 (en) | 2010-12-16 |
| AU2010260585A1 (en) | 2012-01-19 |
| PT2442832E (pt) | 2014-11-11 |
| CN102458476B (zh) | 2014-08-20 |
| HRP20141035T1 (hr) | 2014-12-19 |
| AU2010260585B2 (en) | 2013-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267014A (en) | Preparations and methods for the treatment of autoimmune diseases and other diseases | |
| IL252699A0 (en) | Use of lequinimod to treat multiple sclerosis | |
| EP2603202A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES | |
| EP2473054A4 (en) | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | |
| PL2448581T3 (pl) | Kompozycje terapeutyczne i odnośne sposoby ich stosowania | |
| EP2655334A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
| EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
| HK1166305A1 (zh) | 用於治療炎症的組合物及方法 | |
| HK1167101A1 (en) | Compositions and methods for treatment of multiple sclerosis | |
| EP2550263A4 (en) | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | |
| GB201302653D0 (en) | Pharmaceutical compositions and methods of treatment | |
| IL214455A0 (en) | Methods and compositions for treatment of neovascularization | |
| IL215856A0 (en) | Compositions and methods for treatment of cardiovascular disease | |
| EP2429584A4 (en) | TREATMENT PROCEDURE AND COMPOSITIONS | |
| IL214349A0 (en) | Compositions and methods for the treatment of cancer | |
| EP2405747A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | |
| EP2437738A4 (en) | METHOD AND COMPOSITIONS FOR CANCER TREATMENT | |
| EP2549867A4 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF INJURIES | |
| EP2515652A4 (en) | COMPOSITIONS AND METHODS FOR TREATING VITILIGO | |
| EP2473635A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROPATHIC PAIN | |
| EP2411031A4 (en) | Methods and compositions for the treatment of cancer | |
| HK1166953A1 (en) | Compositions and methods of use | |
| EP2411020A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMORRHAGE | |
| EP2480099A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES | |
| EP2470016A4 (en) | SYNERGISTIC COMPOSITION AND METHOD OF USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190616 |